Precision Biosensor

At a glance

Precision Biosensor filed 36 disclosures in the last 12 months, including 4 insider, 2 5% holder and 1 m&a. The most recent key filing was on Feb 10.

Revenue for 2025 was ₩19.9B, up 4.1% on 2024. It made an operating loss of ₩5.4B. Debt was 62% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩13.2B and operating loss of ₩1.2B.

The 2025 annual report lists 97 employees with an average tenure of 4.2 years and average pay of ₩54.7M, #1235 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩72M each on average. It paid no cash dividend for 2025. 광동제약 주식회사 and related parties held 57.46% at year end.

From the 2025 annual report

Staff: 97 (66 men, 31 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.3B. Directors and auditors: 5, paid ₩360M in total.

No cash dividend was paid for 2025.

Largest shareholder

광동제약 주식회사 holds 54.73%; with 4 related parties the group holds 57.46% of common shares at year end (from 33.92% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary